Bank of Nova Scotia Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Bank of Nova Scotia raised its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 565.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 11,153 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,478 shares during the period. Bank of Nova Scotia’s holdings in Jazz Pharmaceuticals were worth $1,372,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in JAZZ. Kingsview Wealth Management LLC purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at $221,000. New York Life Investment Management LLC boosted its stake in Jazz Pharmaceuticals by 99.7% during the 3rd quarter. New York Life Investment Management LLC now owns 7,266 shares of the specialty pharmaceutical company’s stock valued at $941,000 after purchasing an additional 3,628 shares during the last quarter. Spire Wealth Management boosted its stake in Jazz Pharmaceuticals by 128.6% during the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 238 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth $952,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Jazz Pharmaceuticals by 10.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 513,978 shares of the specialty pharmaceutical company’s stock worth $66,529,000 after buying an additional 46,702 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the sale, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $106.32 on Friday. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The business’s 50-day simple moving average is $110.07 and its two-hundred day simple moving average is $117.82. The stock has a market cap of $6.70 billion, a PE ratio of 21.92, a P/E/G ratio of 1.64 and a beta of 0.62. Jazz Pharmaceuticals plc has a 52 week low of $103.01 and a 52 week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). The business had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. As a group, analysts forecast that Jazz Pharmaceuticals plc will post 15.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Truist Financial restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. UBS Group dropped their price target on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research note on Friday, March 1st. Barclays dropped their price target on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Friday, May 3rd. JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $190.92.

View Our Latest Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Recommended Stories

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.